Market Place
Sourcing Support
DepYmed to Present at the 9th World Rett Syndrome Congress
02 Oct 2024 //
GLOBENEWSWIRE
DepYmed Receives Clearance FDA Initiate Ph1 for DPM-1003 for Rett Syndrome
19 Mar 2024 //
GLOBENEWSWIRE
DepYmed to Meet with Investors at the BIO CEO and Investor Conference
21 Feb 2024 //
GLOBENEWSWIRE
DepYmed to Meet with Investors at the 34th Annual Oppenheimer Conference
07 Feb 2024 //
GLOBENEWSWIRE
DepYmed to Meet with Investors at the Life Sciences Summit
03 Oct 2023 //
GLOBENEWSWIRE
DepYmed to Meet with Investors at the BioFuture Conference in New York City
27 Sep 2023 //
GLOBENEWSWIRE
DepYmed to Meet with Investors at the LSX World Congress USA
08 Sep 2023 //
GLOBENEWSWIRE
DepYmed Presents Developt Update for Small Molecule PTP1B Inhibitor, DPM-1003
15 Jun 2023 //
GLOBENEWSWIRE
DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program
31 May 2023 //
GLOBENEWSWIRE
DepYmed Receives European Medicines Agency Orphan Drug Designation
16 Nov 2022 //
GLOBENEWSWIRE
DepYmed Receives FDA ODD for Clinical Candidate DPM-1001 in Wilson Disease
23 May 2022 //
GLOBENEWSWIRE
DepYmed Receives FDA RPD & ODD for Its Lead Clinical Candidate in Rett Syndrome
03 May 2022 //
GLOBENEWSWIRE
DepYmed and Monash Biomedicine Discovery Institute to Study PTP1B Inhibitors
10 Mar 2022 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.